HanchorBio and Henlius Forge New Path in Immuno-Oncology
HanchorBio and Henlius Form Strategic Alliance for HCB101
HanchorBio Inc. (7827.TWO), a pioneering biotechnology firm focused on innovative immunotherapies for cancer and autoimmune diseases, recently announced a transformative licensing agreement with Shanghai Henlius Biotech, Inc. This landmark deal grants Henlius exclusive rights for the development and commercialization of HCB101 across various regions, including the dynamic markets in Southeast Asia, as well as parts of the Middle East and North Africa.
Key Details of the Licensing Agreement
Through this strategic partnership, HanchorBio is set to receive an upfront payment of USD 10 million. This initial sum is complemented by potential additional payments that could reach up to USD 192 million, contingent on achieving specific developmental and regulatory milestones. Henlius will handle the full scope of development, manufacturing, and commercialization within the licensed areas, while HanchorBio retains its rights internationally.
Innovative Design of HCB101
HCB101 stands out as a novel engineered SIRP?-IgG4 Fc fusion protein, crafted using HanchorBio's proprietary Fc-Based Designer Biologics (FBDB™) platform. Its unique mechanism is designed to obstruct the CD47 "don't eat me" signal, thereby activating macrophage-mediated anti-tumor responses. Impressively, compared to earlier CD47-targeted therapies, HCB101 minimizes hematologic toxicity while providing exceptional efficacy, as evidenced by over 80 tumor models demonstrating its potency.
Promising Phase 1 Study Results
The ongoing global Phase 1 dose-escalation study (NCT05892718) for HCB101 monotherapy has produced promising results, highlighting its favorable safety profile and significant receptor occupancy. Early indications of anti-tumor activity were observed, with two patients showing confirmed partial responses in distinct cancers, which included head and neck squamous cell carcinoma and marginal zone lymphoma.
Expansion into Multi-Regional Trials
After securing approvals from regulatory bodies including the U.S. FDA, HCB101 is advancing into multi-regional Phase 2 trials, focusing on patients suffering from solid tumors and hematologic malignancies. Cancers targeted in these trials include head and neck, gastric, colorectal, and breast cancers, marking an exciting evolution in treatment options for patients.
Statements from Leadership
Dr. Scott Liu, Founder, Chairman, and CEO of HanchorBio, emphasized the significance of this agreement, stating, "This partnership enhances the positioning of HCB101 as a critical asset within the global market and underscores our ongoing commitment to delivering next-generation cancer immunotherapies worldwide." He also expressed optimism about Taiwan's increasing prominence on the global stage.
About HanchorBio
HanchorBio, with its roots in Taipei and an extensive presence in Shanghai and the San Francisco Bay Area, specializes in immunology, aiming to reinvent cancer treatments through innovative therapies. Their proprietary FBDB™ platform facilitates the development of unique biologics targeted at reactivating the immune system, enhancing the fight against cancer. The company is dedicated to breaking through existing treatment barriers while focusing on ensuring accessible therapy for patients globally.
About Henlius
Henlius (2696.HK) is a distinguished biopharmaceutical entity dedicated to providing high-quality and affordable biologic medications worldwide, particularly in oncology and autoimmune areas. Established in 2010, Henlius has a burgeoning portfolio that includes several products in various stages of regulatory approval and market availability, demonstrating its commitment to high-efficiency and innovative solutions in the biopharmaceutical landscape.
Frequently Asked Questions
What is the significance of the licensing agreement between HanchorBio and Henlius?
This licensing deal allows Henlius exclusive rights to develop and commercialize HCB101 in key markets, highlighting the growing collaboration in immuno-oncology.
What is HCB101?
HCB101 is an engineered SIRP?-IgG4 Fc fusion protein designed to target and block the CD47 signal, which helps activate the body's immune response against tumors.
What milestones can trigger additional payments for HanchorBio?
Additional financial milestones are tied to HCB101's development process and regulatory approvals, potentially totaling USD 192 million.
What are the recent study results for HCB101?
The Phase 1 study has shown a favorable safety profile and early signs of efficacy, with several patients experiencing positive treatment outcomes.
What is HanchorBio’s mission?
HanchorBio aims to revolutionize cancer immunotherapy by developing accessible, innovative treatments that effectively harness the immune system in battling cancer.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
